Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Docket No.: A070US

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> **Assistant Commissioner for Patents** Washington, D.C. 20231

December 3, 2002 Date

> Signature Jacqueline L. Marlier

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- 1. General Transmittal Form (1 pg.)
- 2. Copy of International Search Report (7 pgs.)
- 3. Copy of U.S. Application Number 10/077,137 A080US (66 pgs.)
- 4. Copy of U.S. Application Number 10/077,438 A080 USCIP (66 pgs.)
- 5. Copy of U.S. Application Number 10/115,192 A083US (82 pgs.)
- 6. PTO Form 1449 (3 pgs.)
- 7. Information Disclosure Statement Transmittal Form (3 pgs.)
- 8. Information Disclosure Statement Supplemental Communication (2 pgs.)
- 9. Copies of Cited References (AA-AB; BA-BF & CA-CR)
- 10. Return Receipt Postcard





TECH CENTER 1600/2900 DOCKET NO.: A070US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jeffrey Browning, et al.

Application No.:

09/911777

Group Art Unit:

1646

Filed:

July 24, 2001

Examiner:

Haddad, Maher M.

Title:

BAFF, INHIBITORS THEREOF AND THEIR USE IN THE

MODULATION OF B-CELL RESPONSE

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

Dec. 3, 2002

Date

Jacqueline L. Marlier

SUPPLEMENTAL COMMUNICATION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The attached Information Statement Disclosure submitted herewith is being filed before the mailing date of a first Office Action on the merits and therefore no fee is due. In an abundance of caution, however, the Assistant Commissioner is hereby authorized to charge Deposit Account No. 02-2327 for any unforeseen fee that may be due.

In addition to the attached Information Statement Disclosure submitted herewith, Applicants are including a copy of the International Search Report issued for PCT application number PCT/US00/01788, on which the instant U.S. application is based.

If the Examiner believes that consideration of the application, or of any matter related to this submission, would be facilitated by a telephone conference with

Applicants' attorney, the Examiner is urged to contact the undersigned at the telephone number set forth below.

Respectfully submitted,

Timothy P. Linkkila

Reg. No. 40,702 BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 679-3795 (Direct)

(617) 679-2838 (Facsimile)